KẾT QUẢ ĐIỀU TRỊ U LYMPHO TẾ BÀO B LỚN LAN TỎA NGUYÊN PHÁT TINH HOÀN

Abstract

Objective: To evaluate the treatment results of primary testicular large B-cell non-Hodgkin lymphoma. Subjects and methods: A Case series descriptive study was conducted on 14 patients diagnosed with primary testicular B-cell non-Hodgkin lymphoma treated with the RCHOP + MTX regimen and contralateral testicular radiotherapy at the Hematologic Oncology Department, K Hospital from May 2019 to October 2024. Results: Patients had a median age of 62 years; Most patients had PS=0 (71.4%). Most patients were in stage 1, accounting for 57%. The pathology of the non-germinal center type accounted for 85.7%. All patients achieved response, with a complete response rate of 78.6% at interim and 100% at end-of-treatment. The incidence of grade 3-4 leukopenia was 21.4%; febrile leukopenia was 14.3%; hepatitis B virus reactivation was 7.1%; gastrointestinal toxicity was 14.3%; renal failure was grade 1 in 14.3%, grade 3 liver enzyme elevation was 14.3% and pneumonia was 7.1%. Conclusion: The RCHOP + MTX regimen for prevention of central nervous system infiltration and contralateral testicular radiotherapy is highly effective and has acceptable safety in the treatment of primary testicular lymphoma.